Abstract
Gastroesophageal adenocarcinoma is a disease of older adults with very poor survival
rates. Its incidence has risen dramatically across the world in recent decades. Current
treatment approaches for older adults are based largely on extrapolated evidence from
clinical trials conducted in younger and fitter participants than those more commonly
encountered in clinical practice. Understanding how to apply available evidence to
our patients in the clinic setting is essential given the high morbidity of both curative
and palliative treatment. This review aims to use available data to inform the management
of an older adult with gastroesophageal adenocarcinoma.
Abbreviations:
BSC (best supportive care), CAPOX (capecitabine/oxaliplatin), CF (cisplatin/5-fluorouracil), CGA (comprehensive geriatric assessment), CI (confidence interval), CPS (combined positivity score), CRT (chemoradiotherapy), DFS (disease free survival), ECF (epirubicin/cisplatin/5-fluorouracil), ECX (epirubicin/cisplatin/capecitabine), EMR (endoscopic mucosal resection), ERAS (enhanced recovery after surgery), FOLFOX (5-fluorouracil/leucovorin/oxaliplatin), FLOT (5-fluorouracil/leucovorin/oxaliplatin/docetaxel), GA (geriatric assessment), GEA (gastroesophageal adenocarcinoma), GEJ (gastroesophageal junction), Gy (gray), ITT (intention to treat), HR (hazard ratio), ICI (immune checkpoint inhibitor), MRC (medical research council), OS (overall survival), PCR (pathological complete response), PD-L1 (programmed death ligand-1), PFS (progression free survival), RCT (randomized controlled trial), SOX (S-1/oxaliplatin), SOXRT (S-1/oxaliplatin/radiotherapy)Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Geriatric OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2018; 68: 394-424
- A global assessment of the oesophageal adenocarcinoma epidemic.Gut. 2013; 62: 1406-1414
- Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study.World J Gastroenterol. 2007; 13: 1585-1594
- Interactions among smoking, obesity, and symptoms of acid reflux in Barrett’s esophagus.Cancer Epidemiol Biomark Prev. 2005; 14: 2481-2486
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.Lancet. 2019; 393: 1948-1957
- Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.Nat Genet. 2016; 48: 1131-1141
- Comprehensive molecular characterization of gastric adenocarcinoma.Nature. 2014; 513: 202-209
- Oesophageal Cancer.(Available from:)
- Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med. 2008; 358: 36-46
- Gastric cancer.Lancet. 2020; 396: 635-648
- Recent developments in esophageal adenocarcinoma.CA Cancer J Clin. 2013; 63: 232-248
- National Cancer Institute Surveillance and End Results Program (NCI SEER).([cited 2021 16th January]; Available from:)
- Struggling with nutrition in patients with advanced cancer: nutrition and nourishment—focusing on metabolism and supportive care.Ann Oncol. 2018; 29: ii27-ii34
- Changes during aging and their association with malnutrition.J Clin Gerontol Geriatr. 2015; 6: 78-84
- Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study.Lancet. 2012; 380: 37-43
- Minimally invasive esophagectomy in elderly patients.Annals Esophagus. 2019; 2
- Impact of gastric Cancer surgery in elderly patients.Oncology. 2018; 94: 79-84
- The impact of frailty and sarcopenia on postoperative outcomes in older patients undergoing gastrectomy surgery: a systematic review and meta-analysis.BMC Geriatr. 2017; 17: 188
- Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancer.Curr Oncol (Toronto, Ont). 2018; 25: 366-370
- Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.J Clin Oncol. 1999; 17: 2412-2418
- Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.Br J Clin Pharmacol. 2004; 57: 6-14
- Managing medications in clinically complex elders: “There’s got to be a happy medium”.Jama. 2010; 304: 1592-1601
- Association of Proton Pump Inhibitors and Capecitabine Efficacy in advanced Gastroesophageal Cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial.JAMA Oncol. 2017; 3: 767-773
- The prevalence and outcomes of frailty in older cancer patients: a systematic review.Ann Oncol. 2015; 26: 1091-1101
- Impacts of geriatric evaluation and management programs on defined Outcomes: overview of the evidence.J Am Geriatr Soc. 1991; 39: 8S-16S
- Integration of geriatric assessment in the Care of Patients with gastrointestinal malignancies.Visceral Med. 2017; 33: 275-280
- Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.J Clin Oncol. 2019; 37: 4006
- Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal cancer (aGOAC): The uncertain randomization of the GO2 phase III trial.J Clin Oncol. 2019; 37: 4051
- Association of geriatric comanagement and 90-day postoperative mortality among patients aged 75 years and older with Cancer.JAMA Netw Open. 2020; 3: e209265
- Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: A randomized controlled trial.J Clin Oncol. 2020; 38: 12010
- Integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy.J Clin Oncol. 2020; 38: 12011
- A geriatric assessment (GA) intervention to reduce treatment toxicity in older patients with advanced cancer: A University of Rochester Cancer Center NCI community oncology research program cluster randomized clinical trial (CRCT).J Clin Oncol. 2020; 38: 12009
- Nutritional status and interventions for patients with cancer – a systematic review.J Geriatr Oncol. 2021; 12: 6-21
- The impact of Prehabilitation on post-operative Outcomes in Oesophageal Cancer surgery: a propensity score matched comparison.J Gastrointest Surg. 2020; (epub ahead of print)https://doi.org/10.1007/s11605-020-04881-3
- Protocol for enhanced recovery after surgery improves short-term outcomes for patients with gastric cancer: a randomized clinical trial.Gastric Cancer. 2017; 20: 861-871
- Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up<sup>†</sup>.Ann Oncol. 2016; 27: v50-v57
- Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett’s esophagus at two high-volume centers.Ann Surg. 2011; 254: 67-72
- Suitability of the expanded indication criteria for the treatment of early gastric cancer by endoscopic submucosal dissection: Japanese multicenter large-scale retrospective analysis of short- and long-term outcomes.Scand J Gastroenterol. 2015; 50: 413-422
- Long-term outcomes and prognostic factors of endoscopic submucosal dissection for early gastric cancer in patients aged ≥75 years.Cancers (Basel). 2020; : 12(11)
- Patient selection for Oesophagectomy: impact of age and comorbidities on outcome.World J Surg. 2015; 39: 1994-1999
- Predictors of operative death after oesophagectomy for carcinoma.Br J Surg. 2005; 92: 1029-1033
- Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial.Surgical Co-Operative Group Br J Cancer. 1999; 79: 1522-1530
- Surgical outcomes and survival after gastrectomy in octogenarians with gastric cancer.J Surg Res. 2015; 198: 80-86
- Effects of age on survival and morbidity in gastric cancer patients undergoing gastrectomy.World J Gastrointest Oncol. 2017; 9: 257-262
- Feasibility and effectiveness of Gastrectomy for elderly gastric Cancer patients.In Vivo. 2019; 33: 1307-1311
- Feasibility of Gastrectomy with standard lymphadenectomy for patients over 85 years old with gastric Cancer.Ann Surg Oncol. 2015; 22: 3962-3969
- Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.N Engl J Med. 2006; 355: 11-20
- The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).Eur J Cancer. 2013; 49: 835-842
- Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: a meta-analysis based on clinical trials.PLoS One. 2018; 13e0202185
- Preoperative Chemoradiotherapy for esophageal or Junctional Cancer.N Engl J Med. 2012; 366: 2074-2084
- LBA9_PR adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): first results of the CheckMate 577 study.Ann Oncol. 2020; 31: S1193-S1194
- Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).BMC Cancer. 2011; 11: 329
- Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK medical research council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.Lancet Oncol. 2017; 18: 357-370
- EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.BMC Cancer. 2019; 19: 494
- KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.J Clin Oncol. 2018; 36: TPS4136
- VESTIGE: adjuvant immunotherapy in patients with resected esophageal, gastroesophageal junction and gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study.Front Oncol. 2019; 9: 1320
- Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer.J Clin Oncol. 2018; 36: TPS4139
- Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.Jama. 2010; 303: 1729-1737
- Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.Lancet. 2012; 379: 315-321
- Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.J Clin Oncol. 2011; 29: 4387-4393
- Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial.J Clin Oncol. 2019; 37: 1296-1304
- A phase III trial to confirm modified S-1 adjuvant chemotherapy for pathological stage II/III vulnerable elderly gastric cancer patients who underwent gastric resection (JCOG1507, BIRDIE).Jpn J Clin Oncol. 2018; 48: 1101-1104
- Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.J Clin Oncol. 2012; 30: 2327-2333
- Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses.J Clin Oncol. 2015; 33: 3130-3136
- A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial.Ann Oncol. 2021; 32: 368-374
- Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.Cancer. 1993; 72: 37-41
- Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med. 2008; 358: 36-46
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.Lancet Oncol. 2008; 9: 215-221
- Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.Lancet Oncol. 2009; 10: 1063-1069
- Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02.Cancer Chemother Pharmacol. 2015; 75: 319-324
- A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).Br J Cancer. 2017; 116: 472-478
- Efficacy and safety of Pembrolizumab or Pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric Cancer: the KEYNOTE-062 phase 3 randomized clinical trial.JAMA Oncol. 2020; 6: 1571-1580
- LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study.Ann Oncol. 2020; 31: S1192-S1193
- LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study.Ann Oncol. 2020; 31: S1191
- Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).Ann Oncol. 2019; 30: 250-258
- LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study.Ann Oncol. 2020; 31: S1192
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet. 2010; 376: 687-697
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.Lancet Oncol. 2018; 19: 1372-1384
- Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.J Clin Oncol. 2014; 32: 2039-2049
- Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC--A randomized phase III trial.J Clin Oncol. 2016; 34: 443-451
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.Lancet Oncol. 2017; 18: 640-653
- Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers.Br J Cancer. 2021; (epub ahead of print)
- Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.J Clin Oncol. 2021; 39: 4013
- Chemotherapy for patients with advanced gastric cancer with performance status 2.Gastrointest Cancer Res. 2009; 3: 220-224
- Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?.ESMO Open. 2017; 2e000206
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Eur J Cancer. 2011; 47: 2306-2314
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.Lancet Oncol. 2014; 15: 78-86
- Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.J Clin Oncol. 2013; 31: 4438-4444
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol. 2018; 19: 1437-1448
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.Lancet. 2018; 392: 123-133
- Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.J Clin Oncol. 2020; 38: 4503
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2017; 390: 2461-2471
- A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.Gastric Cancer. 2020; 23: 510-519
- Trastuzumab deruxtecan in previously treated HER2-positive gastric Cancer.N Engl J Med. 2020; 382: 2419-2430
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.Lancet Oncol. 2016; 17: 717-726
- Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma.Clin Cancer Res. 2019; 25: 7098-7112
- HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.Oncotarget. 2016; 7: 69060-69074
- Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial.JAMA Oncol. 2018; 4e180013
- Tumor mutational burden as a predictor of immunotherapy response: is more always better?.Clin Cancer Res. 2021; 27: 1236
- Signatures of mutational processes in human cancer.Nature. 2013; 500: 415-421
- Tumor mutational burden determined by panel sequencing predicts survival after immunotherapy in patients with advanced gastric cancer.Front Oncol. 2020; 10: 314
- Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy.Clin Cancer Res. 2020; 26 (clincanres.2085): 1-11
- Research Square.2021
- Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.Lancet Oncol. 2016; 17: 309-318
- Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial.Lancet Gastroenterol Hepatol. 2021; 6: 292-303
- Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: a randomised phase III trial.BMJ Open. 2018; 8e015904
- Early palliative care for patients with metastatic non-small-cell lung cancer.N Engl J Med. 2010; 363: 733-742
- Nutritional management of older adults with gastrointestinal cancers: an International Society of Geriatric Oncology (SIOG) review paper.J Geriatr Oncol. 2018; 9: 382-392
- Palliative therapy for gastric cancer.in: Noh S.H. Hyung W.J. Surgery for Gastric Cancer. Springer, Berlin Heidelberg2019: 295-301
- Early interdisciplinary supportive care in patients with previously untreated metastatic esophagogastric cancer: a phase III randomized controlled Trial.J Clin Oncol. 2021; 0 (JCO.20.01254)
- Inclusion of frail elderly patients in clinical trials: solutions to the problems.J Geriatr Oncol. 2013; 4: 26-31
- Optimising clinical trial design in older cancer patients.Geriatrics (Basel, Switzerland). 2018; 3: 34
- Improving the evidence base for treating older adults with Cancer: American Society of Clinical Oncology statement.J Clin Oncol. 2015; 33: 3826-3833
- End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for clinical trials in oncology--international society of geriatric oncology position article.J Clin Oncol. 2013; 31: 3711-3718
- Understanding the treatment preferences of seriously ill patients.N Engl J Med. 2002; 346: 1061-1066
- Quality of life in elderly cancer patients.Ann Oncol. 2001; 12: S49-S52
- Patient-defined goals and preferences among older adults with cancer starting chemotherapy (CT).J Clin Oncol. 2018; 36: 10009
- Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.N Engl J Med. 2007; 357: 1810-1820
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.Lancet. 2018; 392: 123-133
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2017; 390: 2461-2471
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet. 2014; 383: 31-39
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.Lancet Oncol. 2014; 15: 1224-1235
- Best supportive care and prognosis: advanced gastroesophageal adenocarcinoma..BMJ Supportive and Palliative Care. 2021; (In press)https://doi.org/10.1136/bmjspcare-2020-002637
Article info
Publication history
Published online: September 18, 2021
Accepted:
September 7,
2021
Received in revised form:
August 26,
2021
Received:
March 26,
2021
Identification
Copyright
© 2021 Elsevier Ltd. All rights reserved.
